Department of Medicine, Drexel University College of Medicine, Philadelphia, PA.
Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA.
Am J Transplant. 2017 Dec;17(12):3020-3032. doi: 10.1111/ajt.14403. Epub 2017 Jul 24.
According to the Centers for Disease Control, heart failure (HF) remains a pervasive condition with high morbidity and mortality, affecting 5.8 million people in the United States and 23 million worldwide. For patients with refractory end-stage HF, heart transplantation is the "gold standard" for definitive treatment. However, the demand for heart transplantation has consistently exceeded the availability of donor hearts, with approximately 2331 orthotopic heart transplantations performed in the United States in 2015 despite an estimated 100 000 to 250 000 patients with New York Heart Association class IIIB or IV symptoms that are refractory to medical treatment, making such patients potential transplant candidates. As such, the need for mechanical circulatory support (MCS) to treat patients with end-stage HF has become paramount. In this review, we focus on the history, advancements, and current use of durable MCS device therapy in the treatment of advanced heart failure.
根据疾病控制与预防中心的数据，心力衰竭（HF）仍然是一种普遍存在的疾病，具有高发病率和死亡率，影响美国 580 万人和全球 2300 万人。对于难治性终末期心力衰竭患者，心脏移植是明确治疗的“金标准”。然而，心脏移植的需求一直超过供体心脏的供应，尽管估计有 10 万至 25 万患者出现纽约心脏协会 IIIB 或 IV 级症状且对药物治疗有抗性，但在美国，2015 年仍进行了大约 2331 例原位心脏移植，使这些患者成为潜在的移植候选者。因此，需要机械循环支持（MCS）来治疗终末期心力衰竭患者。在这篇综述中，我们重点介绍了耐用型 MCS 设备治疗在治疗晚期心力衰竭方面的历史、进展和当前应用。
